

Executive	Summary
-----------	---------

Project title	Primary Care Initiation of Anticoagulation Project - North Central & North East London
Project partners	UCL Partners Academic Health Science Network Bayer plc Daiichi Sankyo
Project summary	The project aims to support the development and confidence of GPs to initiate anticoagulation and associated service models to enable CCGs to commission primary-care anticoagulation services using GPs as prescribers. This project has two linked aims; to support the development and confidence of GPs to initiate anticoagulation treatment (as this has traditionally been done by others in the service); and to develop primary care anticoagulation service models involving GPs and using UCL Partners principles of sustainability, developing this further to transfer to other clinicians outside secondary care.
	 Project objectives: 1) Create an integrated care pathway for anticoagulation that is supported by clinical engagement across primary and secondary care 2) Increase the number of patients with newly identified AF who are anticoagulated by GPs thus reducing the waiting times for anticoagulation across the CCG 3) Test 2-3 different models of initiating anticoagulation and evaluate their impact both on clinicians and patients 4) Develop a support package for roll out as part of the pan-London AF improvement programme



Expected benefits to patients, the NHS and Bayer

Benefits for Patients

- Care closer to home
- Reduction in waiting times for
- anticoagulation initiation

• Prevention of serious incidents (which may have been caused by delay in anticoagulation initiation)

Benefits for NHS/UCL Partners Stakeholders

• Reduced mortality – this will be implemented as part of the pan-London AF programme which aims to save 350-450 lives over 5 years and prevent over 300 strokes prevented per annum. (calculated using QOF data from 2014-2015)

• Promote integrated working across clinical boundaries

• More patients receiving NICE recommended treatment for AF in a timely manner

• Developing skills of prescribers

Benefits for Industry Partners

Appropriate NICE approved anti-coagulation medicines including the company's medicines, delivered to more patients in line with national guidelines; including but not limited to NICE Clinical Guideline CG180 Atrial Fibrillation: management, NICE TA256 Rivaroxaban, NICE TA355 Edoxaban NICE TA249 Dabigatran, NICE TA341 Apixaban, for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation.

Start date

May 2017



Executive Summary

Project title	Bradford City Health Federation
	"Non-Valvular Atrial Fibrillation Quality Improvement program (NVAFQIP)"
Project partners	Bradford City Health Federation Daiichi Sankyo UK Ltd
Start date	March 2018

Project summary

Bradford City Health Federation - "Non-Valvular Atrial Fibrillation Quality Improvement program (NVAFQIP)"

Bradford City Health Federation and Daiichi Sankyo UK Ltd have entered into a joint working project entitled the "Non-Valvular Atrial Fibrillation Quality Improvement program (NVAFQIP)"

The overarching aim of this project is to improve the diagnosis rate and prevalence of NVAF and improve the clinical management of new and existing NVAF in primary care. Hence improving the morbidity and mortality of this cohort of NVAF patients via a reduction in Stroke and MI rates in AF patients, a reduction in Emergency and Elective Admissions in NVAF and unexpected preventable deaths from AF and an improved quality of life for patients across the Bradford City area.

Expected benefits to patients, the NHS and Bradford City Health

This is a particular issue for Bradford City CCG area as the prevalence rates are well below the national average and there is a significant group of undiagnosed NVAF patients in the population and varying quality of clinical management across the practices in Bradford. This will save the NHS considerable sums of money by the prevention of NVAF related Strokes and MI.



Executive Summary

Project title

NHS Highland

'Evaluation of post stroke arrhythmia monitoring technologies (R-TEST) to allow appropriate use of oral anticoagulant therapy'

Project partners

NHS Highland Daiichi Sankyo UK Ltd

Start date

March 2019


Project summary

NHS Highland and Daiichi Sankyo UK Ltd have entered into a joint working project entitled 'Evaluation of post stroke arrhythmia monitoring technologies (R-TEST) to allow appropriate use of oral anticoagulant therapy'. This project aims to detect paroxysmal atrial fibrillation (PAF) in patients admitted with stroke to reduce the risk of recurrent stroke by the appropriate use of oral anticoagulation. This project will allow NHS Highland to meet the current national guidelines for monitoring patients following a stroke. The expectation is that up to 16% of patients with cryptogenic stroke will have PAF and will be suitable for anticoagulation. These patients will be identified while inpatients and a consultant led decision about oral anticoagulation made before the patient is discharged. This will reduce future stroke risk with an expected associated reduction in readmission to hospital and saving of bed days.

Expected benefits to patients, the NHS and NHS Highland

This project will enable detection of paroxysmal AF in some patients and appropriate initiation of oral anticoagulation therapy. NHS Highland will also benefit from achieving national standards of care (post stroke monitoring) which was highlighted as a deficiency in a recent national review.

DOP: March 2019. EDX/19/0072



The benefit of this project for Daiichi Sankyo is increase in reputational profile, and the opportunity to work in partnership with the NHS, in which the overall aim is to improve the health and well-being of patients with atrial fibrillation through improved detection and management of the condition.

It is anticipated as part of the project that more patients may be treated with a pharmaceutical product. This may include but is not exclusive to products manufactured by Daiichi Sankyo.



Joint Working	
Executive Summary	
Project title	North Middlesov University Heapitel NHS
	North Middlesex University Hospital NHS Trust
	"North Central London Anticoagulation pathway prioritisation service"
Project partners	North Middlesex University Hospital NHS Trust Daiichi Sankyo UK Ltd
Start date	March 2019

Project summary

North Middlesex University Hospital NHS Trust - "North Central London Anticoagulation pathway prioritisation service"


North Middlesex University Hospital NHS Trust and Daiichi Sankyo UK Ltd have entered into a joint working project entitled the "North Central London Anticoagulation pathway prioritisation service".

The overarching aim of this project is to optimise anticoagulation services to appropriately identify and treat the anticoagulation needs of domiciliary and care home patients, facilitated by the implementation of the NPSA anticoagulation guidelines supporting the safe initiation of DOACs. This will help adherence issues and improve the morbidity and mortality of this cohort of patients via a reduction in Stroke, Emergency and Elective Admissions and unexpected preventable deaths for patients in the North Central London area.

Expected benefits to patients and the NHS & Daiichi-Sankyo

This is a particular issue for domicilliary and care home patients in North Central London as the current patient pathway will be enhanced to properly address their needs and provide them with an anticoagulation service appropriate to their setting. This will save the NHS considerable sums of money by the prevention of Strokes and at the same time improve patient experience of local anticoagulation services.

DOP: March 2019. EDX/19/0094a



The benefit of this project for Daiichi-Sankyo is increase in reputational profile, and the opportunity to work in partnership with the NHS, in which the overall aim is to improve the health and well-being of patients with atrial fibrillation through improved detection and management of the condition.

Additionally, this Joint Working project is intended to create more opportunities for the appropriate use of medicines, including DAIICHI SANKYO UK's medicines in suitable patients in line with NICE treatment guidelines and the NPSA anticoagulation guidelines. If this improvement occurs, we are likely to see an increase in DOAC prescriptions including Lixiana.



Executive Summary

Project title

AF Quality Audit

Project partners

Health Innovation Network (HIN) AHSN (on behalf of Southwark CCG) and Daiichi Sankyo UK Ltd

Start date

September 2019

Project summary

Anticoagulation in clinical practice has undergone a transformation since the introduction of the direct oral anticoagulants (DOACs). Until then the primary option for treatment was warfarin and patients were under the long-term care of anticoagulant specialists. Now anticoagulation therapy can be initiated and monitored by a range of clinicians across primary care (GPs, nurses, pharmacists) and secondary care (cardiology, stroke, care of the elderly, general medicine). Whilst this change in practice has improved access to anticoagulation, there are concerns regarding the quality and safety of prescribing practice particularly choice of drug, dose prescribed and the monitoring undertaken. This project seeks to undertake an audit of DOAC prescribing in primary care to assess whether local prescribing practice is safe and effective.

Expected benefits to patients, the NHS and Daiichi-Sankyo

This project provides the assurance that the prescribing of DOACs in Southwark CCG is safe and effective. Also to develop the evidence of the quality and safety of prescribing of DOACs and a systematic process to maintain the safe an effective prescribing of DOACs.

The benefit of this project for Daiichi-Sankyo is increase in reputational profile, and the opportunity to work in partnership with the Health Innovation Network (HIN) AHSN, in which



the overall aim is to improve the health and well-being of patients with atrial fibrillation through improved management of the condition.

It is anticipated as part of the project that more patients may be treated with a pharmaceutical product. This may include but is not exclusive to products manufactured by Daiichi-Sankyo.